Medtronic's Q4 2026 commentary indicates valve procedures demand has stabilized after a slowdown, with U.S. headwinds from low-risk data and large-size valve use. Management also underscores a strategic, accelerating investment in DASI software for mitral and tricuspid care, signaling execution momentum and an optimistic outlook.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What did management say about Valve procedures demand and DASI software?
Management characterized demand for the (older) valve procedure technology as having stabilized after a slowdown. Specifically, they said the business “has stabilized” and that over the last 8 to 10 weeks it’s been stable, while noting they experienced a slowdown in growth tied to low-risk data (described as a U.S. dynamic) and that the procedure tactics have changed and are limited to a large-size valve used primarily in the U.S. 1.
They also reinforced the same point with more direct demand/procedure language: they stated that weekly U.S. procedure volumes have stabilized over the last 8 weeks, which is the trajectory they incorporated into their outlook 2, and later summarized that in Q4 they grew 6.6% despite a headwind from TAVR (particularly in the U.S.) and that the stabilization over the last 8 weeks is what they modeled going forward 3.
Net takeaway: management did not frame valve/TAVR demand as collapsing; rather, they described a period of slowdown and U.S.-specific headwinds (low-risk data, procedure tactics/large-size valve limitation), followed by stabilization that supported their modeling 123.
Management tied DASI software to a specific investment focus within Structural Heart / heart valve-related work. They said they are “heavily investing” in the business and specifically mentioned investing in “this DASI software,” adding that they have mitral and tricuspid components within that effort 1.
They also expressed confidence in execution going forward, stating they have “new, fresh leadership … running fast” related to that area and that they are “feeling good going forward” 1.
Net takeaway: management’s message on DASI was both strategic (a named software investment with mitral/tricuspid) and execution-oriented (confidence supported by leadership and pace of rollout) 1.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Medtronic reports that demand for valve procedures, particularly TAVR, has stabilized in the U.S. after a brief slowdown linked to low-risk data and market dynamics, guiding a steadier near-term outlook. The company is accelerating investment in DASI software within Structural Heart, supported by leadership changes and momentum, with a focus on mitral and tricuspid capabilities and an optimistic path forward.
Sources used
Research questionWhat did management say about Valve procedures demand and DASI software?
Answer outline
Medtronic's FY27 organic growth target of 5.5%-6% (excluding the extra selling week) rests on sustained CAS momentum and a diversified driver set across Neuroscience, Cardiovascular, and MiniMed/MedSurg contributions, supported by CRM innovations and Ardian growth.
Sources used
Research questionWhat drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Answer outline
Medtronic pins FY27 organic growth at about 5.5% to 6%, supported by Neuroscience acceleration and sustained MedSurg momentum, while CAS remains a strong contributor. MiniMed adds a modest uplift, and the company emphasizes that CAS will not slow, underpinning the diversified path to the target.
Sources used
Research questionWhat drives the 5.5%-6% organic growth guidance for FY27 excluding the extra selling week, and which segments offset CAS to support that outlook?
Answer outline
Medtronic asserts that Affera utilization is strongest at high-volume centers, with 75% of the U.S. installed base and ongoing expansion through additional systems and broader penetration into lower-volume sites. Management ties utilization to quarterly pull-through and notes the installed-base ramp is in early innings, supported by clinical evidence, reimbursement, and ecosystem initiatives to unlock a larger market opportunity.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
Medtronic reports robust Q1 2027 base business outside CAS, led by CRM, CST, and Surgical, with Altaviva offsetting SNM softness. The Cornerstone investment is a $700 million global initiative driving long-term growth, but near-term revenue timing is not disclosed, and management reduced the operating-margin expansion guidance by about 10 bps to fund reinvestments.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic reports a broad-based uplift in its base business excluding CAS for Q1 FY2027, led by CRM, CST, and Surgical strengths, with Altaviva beginning to contribute as reimbursement and training efforts scale. The Cornerstone investment is framed as a longer-term, globally focused platform that may deliver revenue gradually, while the company trims near-term operating-margin expansion by ~10 basis points to fund growth initiatives. Organic revenue guidance is raised despite the investment backdrop.
Sources used
Research questionPlease provide an update on Medtronic's base business excluding CAS, including Altaviva performance, plus details on the Cornerstone deal (timing of revenue impact in base Surgical, contract structure, geographic scope including whether the U.S. is included), and the margin guidance change (clarify the rationale behind lowering the operating profit margin expansion guidance by about 10 basis points)?
Answer outline
Medtronic indicates Affera utilization expansion is in the early adopters stage, driven by high-volume centers with room to penetrate lower-volume accounts. Management notes strong pull-through within existing large accounts, rapid installed-base growth, and the perception of Affera as a workhorse technology, while acknowledging the lack of precise utilization metrics to quantify pace or ceiling.
Sources used
Research questionWhat did management say about Affera center utilization expansion?
Answer outline
Moderna did not set a numeric approval threshold or confirm a 2027 pivotal-data timeline for mRNA-4359 in melanoma. For mRNA-2808, management highlighted safety, response occurrence and durability in heavily pretreated myeloma, but did not provide numeric success criteria or describe a plan to study the therapy earlier in the treatment pathway.
Sources used
Research questionFor mRNA-4359, what efficacy bar would support approval in first- or second-line melanoma, and could it produce pivotal data in 2027? For the T-cell engager in multiple myeloma, what would constitute positive data in a refractory population, and is there a strategy to study it earlier in the treatment pathway?
Answer outline
Management frames AI-driven deployment automation as a long-term aspiration, envisioning agents that understand a customer's environment, potentially replace an incumbent product in under a week, and operate with limited human input. Adoption hinges on customer readiness, governance, and integration work, while a data-first architecture and telemetry enable faster detection, response, and automated remediation across deployments.
Sources used
Research questionWhat did management say about AI-driven automation for customer deployments?
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Marvell outlines a broad expansion of CXL beyond server memory into AI inference enablement, with Structera positioned within a growing memory-expansion ecosystem. The update also shows scale-up optics gaining momentum, with NPO and CPO contributions expanding beyond Celestial references, and management signaling a diversified, end-to-end optical strategy across multiple workloads and architectures.
Sources used
Research questionGive an architectural update on CXL evolution (including Structera) and the broader ecosystem, and provide an update on scale‑up optics progress versus the Celestial AI targets?
Answer outline
Best Buy’s August results show a mixed back-half trajectory: seasonal back-to-school demand and NFL traffic support activity, while the Windows 10 headwind in computing tempers broader momentum. AI-enabled features, longer battery life, and gaming are expanding upgrade reasons beyond pure replacement, while Apple price-increase pull-forward remains modest and not material for the quarter.
Sources used
Research questionFor August and beyond, is there a back-half tailwind, and how is computing demand split between replacement versus AI cycle, and is there evidence of demand pull-forward from Apple's price increases?
Answer outline
Dafinchi